Weight management · Phase 2
MariTide: phase 2 obesity and diabetes cohorts
What was tested?
Maridebart cafraglutide versus placebo in separate cohorts with obesity, with or without type 2 diabetes. ↗
Registered primary question: Percentage change in body weight at week 52. ↗
What the reviewed report found
Journal year 2025 · Article summary reviewed 2026-09-15
In the intention-to-treat analysis, weight changes ranged from −12.3% to −16.2% versus −2.5% without diabetes, and −8.4% to −12.3% versus −1.7% with diabetes. Gastrointestinal events were common.↗
Keep in context: The 592 randomized participants included 465 without diabetes and 127 with type 2 diabetes. These cohorts and the treatment-policy and efficacy estimates should remain separate. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 592 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 18 Years to 99 Years
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2026-01-20; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Phase 2 obesity trial
- Design in the report
- Randomized, placebo-controlled 52-week trial with multiple active groups; NCT05669599.↗
- Participants in the report
- 592 participants: 465 with obesity without diabetes and 127 with obesity and type 2 diabetes.↗
- Limitations
- Multiple groups and two populations should not be pooled into a single effect. Weight is not a direct measure of cardiovascular outcomes, and longer-term safety remains unresolved.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus ↗
Protocol identifier: 20190218. Sponsor: Amgen.
Retrieved 2026-09-20; SHA-256 9e9f041791a3a6a56e9849cd26473df206cb7e8a414648d702bbdd97761f2bea.
PMID 40549887
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference BACKGROUND. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 40549887. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 2fa875a73469b01b029c1019de493000ec6d2baebd858aae8cde64d452caf1d1.